MAPT and Alzheimer disease: We also evaluated the clinical significance of the dynamic multilayer FC measures by examining their association with the extent of brain pathology using amyloid-PET and tau-PET measures as well as the scores of global cognitive and memory tests that are frequently employed in clinical settings to evaluate individuals with signs of AD.